GTC
XFOR icon

Ghost Tree Capital’s X4 Pharmaceuticals XFOR Stock Holding History

Ghost Tree Capital’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-28,333
Closed -$740K – 69
2023
Q1 		$740K Sell
28,333
-5,000
-15% -$147K 0.22% 52
2022
Q4 		$993K Buy
+33,333
New +$1.58M 0.42% 32

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Ghost Tree Capital's XFOR Position: Q2 2023 in Review

Ghost Tree Capital sold out of X4 Pharmaceuticals (XFOR) in Q2 2023, closing a stake of 28,333 shares — an estimated $740K sold.

Ghost Tree Capital first reported a position in XFOR in Q4 2022 and held it in 2 quarters. The position peaked at $993K in Q4 2022. 95 funds tracked by Wall St. Rank hold XFOR as of Q2 2023.

  • Ghost Tree Capital reported no remaining X4 Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 28,333 X4 Pharmaceuticals shares in Q2 2023, an estimated $740K.
  • Ghost Tree Capital first reported a position in X4 Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Ghost Tree Capital's X4 Pharmaceuticals position peaked at $993K in Q4 2022.
  • 95 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2023.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.